Rapport Therapeutics (RAPP) Free Cash Flow (2023 - 2026)

Rapport Therapeutics (RAPP) has reported Free Cash Flow for 4 consecutive years, with -$13.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Free Cash Flow rose 35.96% year-over-year to -$13.1 million; the TTM figure through Mar 2026 stood at -$80.7 million (down 16.84% YoY), while the FY2025 annual figure was -$88.1 million, down 31.02% from the prior year.
• Free Cash Flow climbed to -$13.1 million in Q1 2026 per RAPP's latest filing, from -$24.9 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$5.5 million in Q3 2023 and bottomed at -$25.1 million in Q2 2025.
• Historically, Free Cash Flow has averaged -$16.9 million across 4 years, with a median of -$17.3 million in 2024.
• Annual changes were most pronounced in 2024 — Free Cash Flow plunged 202.32% — and 2026, when it surged 35.96%.
• Rapport Therapeutics' Free Cash Flow stood at -$11.8 million in 2023, then fell by 24.4% to -$14.7 million in 2024, then sank by 69.51% to -$24.9 million in 2025, then soared by 47.14% to -$13.1 million in 2026.
• Business Quant data shows RAPP's Free Cash Flow at -$13.1 million in Q1 2026, -$24.9 million in Q4 2025, and -$17.6 million in Q3 2025.